Indeed, the results collected in our experimental conditions suggest that the interference with the CCL20/CCR6 axis, achieved not through CCR6 gene deletion but via pharmacological modulation, does not appear to exacerbate the colitis induced by the lack of Treg cells, while only colonic MPO reduction was observed, not comparable with the systemic and local beneficial effects previously shown by MR120 on DSS- and TNBS-induced colitis models. The gene discussed is CCR6; the disease is colitis.